Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. Yuzhuo Wang

Yuzhuo Wang

Professor
Academic Appointment
Professor
Research Focus
Prostate Cancer
Degrees / Designations
PhD, MD, FCAHS
Contact Info
yuzhuo.wang@ubc.ca
604-675-8013
yuzhuo-wang-7bb76410/

Biography

Dr. Yuzhuo Wang has a dual appointment as a distinguished scientist at the BC Cancer and senior scientist at the Vancouver Prostate Centre. He is a professor in the Department of Urologic Sciences at the University of British Columbia (UBC) and the founder of the unique Living Tumor Laboratory. Dr. Wang has authored or co-authored over 190 peer-reviewed articles and 14 book chapters and edited two books related to PDX models of human cancer and tumor dormancy.

Dr. Wang is renowned for his pioneering work in the field of cancer modeling. He created a novel method for establishing patient-derived xenograft (PDX) cancer models that closely resemble patients’ malignancies from which they are derived. His group has established over 300 high fidelity next generation PDX models of a variety of malignancies in his Living Tumor Laboratory. His next generation PDX cancer models have been effectively applied in a number of research areas, including preclinical drug efficacy studies, discovery and validation of potential biomarkers and therapeutic targets, and evidence-based personalized cancer therapy.

Dr. Wang’s scholarly contributions can be highlighted by a number of novel hypotheses he has proposed, such as hypotheses on prostate stem cells, epithelial-immune cell transition (EIT), cancer-generated lactic acid as a critical, immunosuppressive metabolite rather than a ‘waste product’ and tumor dormancy as a non-genetic disease. Based on his innovative theories and ideas, he has maintained an extraordinarily high level of grant funding that have led to widely recognized, ground-breaking research, including the discovery of several new therapeutic targets and the development of novel therapeutics targeting, among others, GATA2, BIRC6, MCT4, HP1-alpha and B7H4 genes. Based on his discoveries, three biotech companies have been formed in Canada. He has been mentoring over 50 co-op students, graduate students and postdoctoral fellows. To date, many of them are employed as clinical doctors, academic professors and scientists in industry.

Dr. Wang’s international reputation is widespread. He has been invited to give more than 180 lectures worldwide including at the most prestigious prostate cancer meetings. He has received many awards for his academic achievements in cancer research including a Prostate Cancer Foundation (US) Research Award in 2007, the Translation Research Award from Roche Canada in 2009, the Innovative Scholar Award from the International Cancer Alliance for Research and Education (ICARE), US in 2010, a UBC Faculty of Medicine Distinguished Achievement Award in 2011, a Department of Urologic Sciences Research Teaching Excellence Award in 2015, three UBC Department of Urologic Sciences Outstanding Academic Performance Awards in 2013, 2017 and 2019, and a Movember – PCF Challenge (US) Award in 2020. Notably, he has been inducted as a Fellow of the Canadian Academy of Health Sciences (FCAHS) since September 2018.

Publications

  • Nature reviews. Urology -

    Molecular events in neuroendocrine prostate cancer development.

    Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y
  • International journal of molecular sciences -

    Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity.

    Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, Wang Y
  • Nature communications -

    ONECUT2 is a driver of neuroendocrine prostate cancer.

    Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH
  • European urology -

    Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

    Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y
  • Cancer research -

    Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

    Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y
Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy